Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2011-2-2
pubmed:abstractText
We sought to evaluate the safety and efficacy of TG4001 in patients with human papillomavirus (HPV) 16-related cervical intraepithelial neoplasia (CIN) 2/3 at 6 and 12 months.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1097-6868
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 Mosby, Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
204
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
169.e1-8
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy.
pubmed:affiliation
Department of Obstetrics and Gynecology, University Hospital of Bordeaux, Laboratory of Virology, University of Bordeaux, Bordeaux, France. jean-luc.brun@chu-bordeaux.fr
pubmed:publicationType
Journal Article, Multicenter Study, Clinical Trial, Phase II